CONMED (CNMD) Expected to Announce Earnings on Wednesday

CONMED (NYSE:CNMD) will likely be posting its Q4 2025 results after the market closes on Wednesday, January 28th. Analysts expect CONMED to post earnings of $1.32 per share and revenue of $366.8820 million for the quarter. CONMED has set its FY 2025 guidance at 4.480-4.530 EPS. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, January 28, 2026 at 4:30 PM ET.

CONMED (NYSE:CNMD) last announced its earnings results on Wednesday, November 5th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. CONMED had a net margin of 4.75% and a return on equity of 14.22%. The company had revenue of $337.93 million during the quarter, compared to the consensus estimate of $334.76 million. During the same quarter in the prior year, the company posted $1.05 earnings per share. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. On average, analysts expect CONMED to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

CONMED Stock Down 1.6%

CNMD opened at $40.96 on Tuesday. CONMED has a fifty-two week low of $38.32 and a fifty-two week high of $74.70. The firm has a market capitalization of $1.27 billion, a P/E ratio of 19.98, a PEG ratio of 1.87 and a beta of 0.96. The company’s 50-day moving average is $41.58 and its 200 day moving average is $46.63. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.10 and a quick ratio of 0.95.

Analysts Set New Price Targets

CNMD has been the topic of several recent analyst reports. Zacks Research cut shares of CONMED from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 1st. JPMorgan Chase & Co. dropped their price target on CONMED from $58.00 to $52.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th. Weiss Ratings restated a “sell (d+)” rating on shares of CONMED in a research note on Wednesday, January 21st. Piper Sandler decreased their target price on CONMED from $68.00 to $55.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Finally, Wells Fargo & Company reduced their price target on shares of CONMED from $57.00 to $47.00 and set an “equal weight” rating for the company in a research report on Thursday, November 6th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $53.67.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CNMD. California State Teachers Retirement System lifted its holdings in shares of CONMED by 1.6% in the second quarter. California State Teachers Retirement System now owns 28,522 shares of the company’s stock worth $1,485,000 after buying an additional 442 shares in the last quarter. Kelleher Financial Advisors purchased a new position in CONMED during the third quarter valued at approximately $28,000. Quarry LP increased its holdings in CONMED by 244.8% during the 3rd quarter. Quarry LP now owns 869 shares of the company’s stock worth $41,000 after acquiring an additional 617 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in CONMED by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,354 shares of the company’s stock worth $1,108,000 after purchasing an additional 800 shares in the last quarter. Finally, Swiss National Bank lifted its stake in CONMED by 1.5% in the 3rd quarter. Swiss National Bank now owns 60,000 shares of the company’s stock worth $2,822,000 after purchasing an additional 900 shares in the last quarter.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.